Literature DB >> 12411494

The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

Agata Klejman1, Steven J Schreiner, Malgorzata Nieborowska-Skorska, Artur Slupianek, Matthew Wilson, Thomas E Smithgall, Tomasz Skorski.   

Abstract

Signal transducer and activator of transcription 5 (STAT5) is constitutively activated by BCR/ABL, the oncogenic tyrosine kinase responsible for chronic myelogenous leukemia. The mechanism of BCR/ABL-mediated STAT5 activation is unknown. We show here that the BCR/ABL SH3 and SH2 domains interact with hematopoietic cell kinase (Hck), leading to the stimulation of Hck catalytic activity. Active Hck phosphorylated STAT5B on Tyr699, which represents an essential step in STAT5B stimulation. Moreover, a kinase-dead Hck mutant and Hck inhibitor PP2 abrogated BCR/ABL-dependent activation of STAT5 and elevation of expression of STAT5 downstream effectors A1 and pim-1. These data identify a novel BCR/ABL-Hck-STAT5 signaling pathway, which plays an important role in BCR/ABL-mediated transformation of myeloid cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411494      PMCID: PMC131059          DOI: 10.1093/emboj/cdf562

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  64 in total

1.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

Authors:  T Skorski; A Bellacosa; M Nieborowska-Skorska; M Majewski; R Martinez; J K Choi; R Trotta; P Wlodarski; D Perrotti; T O Chan; M A Wasik; P N Tsichlis; B Calabretta
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

2.  The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr.

Authors:  M Warmuth; M Bergmann; A Priess; K Häuslmann; B Emmerich; M Hallek
Journal:  J Biol Chem       Date:  1997-12-26       Impact factor: 5.157

Review 3.  Signal transduction by wild-type and leukemogenic Abl proteins.

Authors:  A B Raitano; Y E Whang; C L Sawyers
Journal:  Biochim Biophys Acta       Date:  1997-12-09

4.  P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members.

Authors:  R L Ilaria; R A Van Etten
Journal:  J Biol Chem       Date:  1996-12-06       Impact factor: 5.157

Review 5.  The state of the STATs: recent developments in the study of signal transduction to the nucleus.

Authors:  C M Horvath; J E Darnell
Journal:  Curr Opin Cell Biol       Date:  1997-04       Impact factor: 8.382

6.  The Bmx tyrosine kinase induces activation of the Stat signaling pathway, which is specifically inhibited by protein kinase Cdelta.

Authors:  P Saharinen; N Ekman; K Sarvas; P Parker; K Alitalo; O Silvennoinen
Journal:  Blood       Date:  1997-12-01       Impact factor: 22.113

7.  SH3-mediated Hck tyrosine kinase activation and fibroblast transformation by the Nef protein of HIV-1.

Authors:  S D Briggs; M Sharkey; M Stevenson; T E Smithgall
Journal:  J Biol Chem       Date:  1997-07-18       Impact factor: 5.157

8.  Intramolecular interactions of the regulatory domains of the Bcr-Abl kinase reveal a novel control mechanism.

Authors:  H J Nam; W G Haser; T M Roberts; C A Frederick
Journal:  Structure       Date:  1996-09-15       Impact factor: 5.006

9.  The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing.

Authors:  T Skorski; M Nieborowska-Skorska; P Wlodarski; M Wasik; R Trotta; P Kanakaraj; P Salomoni; M Antonyak; R Martinez; M Majewski; A Wong; B Perussia; B Calabretta
Journal:  Blood       Date:  1998-01-15       Impact factor: 22.113

10.  Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.

Authors:  S K Chai; G L Nichols; P Rothman
Journal:  J Immunol       Date:  1997-11-15       Impact factor: 5.422

View more
  62 in total

1.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.

Authors:  Kamalika Moulick; James H Ahn; Hongliang Zong; Anna Rodina; Leandro Cerchietti; Erica M Gomes DaGama; Eloisi Caldas-Lopes; Kristin Beebe; Fabiana Perna; Katerina Hatzi; Ly P Vu; Xinyang Zhao; Danuta Zatorska; Tony Taldone; Peter Smith-Jones; Mary Alpaugh; Steven S Gross; Nagavarakishore Pillarsetty; Thomas Ku; Jason S Lewis; Steven M Larson; Ross Levine; Hediye Erdjument-Bromage; Monica L Guzman; Stephen D Nimer; Ari Melnick; Len Neckers; Gabriela Chiosis
Journal:  Nat Chem Biol       Date:  2011-09-25       Impact factor: 15.040

2.  Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.

Authors:  Teodora Pene-Dumitrescu; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

Review 3.  Applying the discovery of the Philadelphia chromosome.

Authors:  Daniel W Sherbenou; Brian J Druker
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

4.  Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.

Authors:  Geoffrey A Bartholomeusz; Moshe Talpaz; Vaibhav Kapuria; Ling Yuan Kong; Shimei Wang; Zeev Estrov; Waldemar Priebe; Ji Wu; Nicholas J Donato
Journal:  Blood       Date:  2007-01-03       Impact factor: 22.113

Review 5.  Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis.

Authors:  Daniel E Johnson
Journal:  Adv Enzyme Regul       Date:  2007-11-19

6.  Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R.

Authors:  Zhi Sheng; Shu-Zong Wang; Michael R Green
Journal:  EMBO J       Date:  2009-02-19       Impact factor: 11.598

Review 7.  Following the cytokine signaling pathway to leukemogenesis: a chronology.

Authors:  Kendall A Smith; James D Griffin
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

Review 8.  Targeted therapy of chronic myeloid leukemia.

Authors:  Con Sullivan; Cong Peng; Yaoyu Chen; Dongguang Li; Shaoguang Li
Journal:  Biochem Pharmacol       Date:  2010-05-12       Impact factor: 5.858

9.  In Vitro Evolution Reveals a Single Mutation as Sole Source of Src-Family Kinase C-Helix-out Inhibitor Resistance.

Authors:  Ravi K Patel; Yash K Patel; Thomas E Smithgall
Journal:  ACS Chem Biol       Date:  2020-07-15       Impact factor: 5.100

10.  Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.

Authors:  A K Samanta; S N Chakraborty; Y Wang; H Kantarjian; X Sun; J Hood; D Perrotti; R B Arlinghaus
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.